Individualized Treatment Approaches for Langerhans Cell Histiocytosis

Publication

Individualized Treatment Approaches for Langerhans Cell Histiocytosis

Journal Paper/Review - Nov 30, 2017

Roider E, Dummer R, French L E, Cozzio Antonio, Hoetzenecker W, Jochum W, Balabanov S, Kerl K, Kamarachev J, Schaller M, Metzler G, Fehrenbacher B, Signer C, Guenova E

Citation

Roider E, Dummer R, French L, Cozzio A, Hoetzenecker W, Jochum W, Balabanov S, Kerl K, Kamarachev J, Schaller M, Metzler G, Fehrenbacher B, Signer C, Guenova E. Individualized Treatment Approaches for Langerhans Cell Histiocytosis. Br J Dermatol 2017

Type

Journal Paper/Review (English)

Journal

Br J Dermatol 2017

Publication Date

Nov 30, 2017

Issn Electronic

1365-2133

Brief description/objective

Langerhans cell histiocytosis (LCH) belongs to the rare histiocytic disorders, and has an estimated incidence of 1-2 cases per million adults [1]. Myeloid dendritic cells that express the same antigens (CD1a, CD207) as epidermal Langerhans cell seem to be the precursor cells for LCH [2]. Clinical presentation of patients with LCH may vary in site and extent of involvement. In 45% of patients LCH manifests as a multisystem disease including 77% bone, 39% skin, 19% lymph node, 16% liver, 13% spleen, 13% oral mucosa, 10% lung, and 6% CNS involvement [3]. This article is protected by copyright. All rights reserved.